Cantor Fitzgerald initiated coverage of TriSalus Life Sciences (TLSI) with an Overweight rating and $10 price target
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TLSI:
- TriSalus Life Sciences management to meet with Maxim
- TriSalus Life Sciences price target lowered to $11 from $12 at Canaccord
- TriSalus Life Sciences Reports Strong Q3 Growth
- TriSalus Life Sciences reports Q3 EPS (12c), consensus (37c)
- TriSalus Life Sciences sees FY25 revenue growth ‘more than 50%’
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
